Search
Learn about the goals of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research: to reveal more about the biology of lung cancer, to examine novel treatment approaches, and to bring promising new therapies to our patients.
Meet three people who were treated as part of a clinical trial for melanoma at Memorial Sloan Kettering.
The global prize is awarded annually to a researcher, physician, or team leader who has made a positive and lasting impact in the fight against pediatric cancer.
With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center.
Learn about MSK’s visionary new cancer engineering PhD Program.
MSK researchers are learning more about how cancer cells can survive undetected for years only to return in new places. These insights will guide future therapies.
After 21 years of dedicated service, Elizabeth McCormick, MSN, RN, CENP, Senior Vice President, Chief Nursing Officer and Enid A. Haupt Chair, Department of Nursing, will retire from MSK at the end of 2021. During her tenure, Ms. McCormick transformed and ultimately redefined the role of nursing at MSK.
Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.
The effects of adoptive T cell therapy on mesothelioma and metastatic lung and breast cancers are the focus of a new Memorial Sloan Kettering Cancer Center trial, which, compared to some existing trials of therapy, offers some important differences for patients.
Maria Jasin, a member of the Sloan Kettering Institute’s Developmental Biology Program, discusses her research.